Equity · Healthcare
DYN
NASDAQDyne Therapeutics (DYN)
The line runs 26 USD on 12 August through 26.37 USD on 26 August, on a scale from 25.5 to 27.0. Days the market did not trade hold the previous close, flat.
- Market cap
- 4.9B USD
- EPS, diluted, year to Dec 2025
- −3.47 USD
- 52-week range
- 12 USD – 26.80 USD
- Avg volume
- 399.2K
as of Aug 26, 2026
Have Dyne Therapeutics (DYN) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Dyne Therapeutics insiders reported 11 open-market sales and 1 purchase (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest reported trade 2 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Oct 2026 | Posner Brian SDirector | Buy | 2,500 | 40K USD |
| 08 Sep 2026 | Friedl-Naderer JohannaChief Commercial Officer | Sell | 185 | 3K USD |
| 08 Sep 2026 | Kerr DouglasChief Medical Officer | Sell | 1,290 | 24K USD |
| 08 Sep 2026 | Cox JohnCEO & President | Sell | 5,658 | 107K USD |
| 04 Sep 2026 | Friedl-Naderer JohannaChief Commercial Officer | Sell | 900 | 22K USD |
| 04 Sep 2026 | Kerr DouglasChief Medical Officer | Sell | 3,745 | 91K USD |
| 14 Aug 2026 | Rhodes Jason PDirector | Sell | 2,160,516 | 54.0M USD |
| 13 Aug 2026 | Rhodes Jason PDirector | Sell | 426,412 | 11.2M USD |
| 13 Aug 2026 | Friedl-Naderer JohannaChief Commercial Officer | Sell | 226 | 6K USD |
| 13 Aug 2026 | Kerr DouglasChief Medical Officer | Sell | 1,556 | 41K USD |
| 13 Aug 2026 | Lucera ErickChief Financial Officer | Sell | 1,797 | 47K USD |
| 13 Aug 2026 | Cox JohnCEO & President | Sell | 4,986 | 131K USD |
| Bought | 1 open-market purchase | 2,500 | $40K | |
| Sold | 11 open-market sales | 2,607,271 | $65.66M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 20 Oct 2026 | Kerr DouglasHead of R&D and CMO | Award | 8,000 |
Which funds hold Dyne Therapeutics (DYN)?
1 of the 45 institutional funds we track reported a Dyne Therapeutics position for the quarter ended 30 Sep 2026 — a combined 4.2M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 259,024 | 4.2M USD | −13.2% |
What has been filed or recorded for Dyne Therapeutics (DYN)?
The filings we hold for Dyne Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,492 shares | 56K USD notional · 0.002% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,440 shares | 155K USD notional · 0.005% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,114 shares | 50K USD notional · 0.002% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.06 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 930.9M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.08 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.73 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.47 USD | |
| 31 Dec 2025 | Financials | Net income | −446.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.47 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.76 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.97 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.05 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.37 USD |
What do people ask about Dyne Therapeutics (DYN)?
What did Dyne Therapeutics shares close at?26.37
Dyne Therapeutics closed at 26.37 USD on 26 Aug 2026, up 0.06% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Dyne Therapeutics’ market cap?4.9B
Dyne Therapeutics is worth 4.9B USD by market value as of 26 Aug 2026, which is the share price times the shares on issue from its SEC filings.
Have Dyne Therapeutics insiders bought or sold shares recently?11 sales
In the 90 days to 10 Nov 2026, Dyne Therapeutics insiders reported 11 open-market sales and 1 purchase (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Dyne Therapeutics?1 of 45
1 of the 45 funds we track reported a Dyne Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Dyne Therapeutics last report earnings?−1.06
Dyne Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.06 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings